This Viewpoint discusses the challenges of high prices for payers and high access barriers for patients for specialty drugs and how these can be addressed by value-based pricing and value-based patient access.
No takes yet. Share an insight, caveat, or question.
Robinson et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: